Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection
Dolutegravir (DTG) + lamivudine (3TC) dual therapy regimen has entered the guidelines as a preferred first-line treatment regimen in antiretroviral treatment naïve individuals and as a switch regimen in cases with virologic suppression. Although clinical studies and real-life data suggest that virol...
محفوظ في:
| المؤلفون الرئيسيون: | , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Infectious Diseases and Clinical Microbiology Specialty Society of Turkey
2022-12-01
|
| سلاسل: | Mediterranean Journal of Infection, Microbes and Antimicrobials |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://www.mjima.org/text.php?&id=356 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|